Everett Harris & Co. CA Invests $84.13 Million in Becton, Dickinson and Company $BDX

Everett Harris & Co. CA purchased a new position in shares of Becton, Dickinson and Company (NYSE:BDX) in the 2nd quarter, according to its most recent Form 13F filing with the SEC. The firm purchased 555,953 shares of the medical instruments supplier’s stock, valued at approximately $84,132,000. Becton, Dickinson and Company comprises about 1.0% of Everett Harris & Co. CA’s investment portfolio, making the stock its 21st largest holding.

Several other institutional investors have also added to or reduced their stakes in BDX. Imprint Wealth LLC bought a new position in Becton, Dickinson and Company during the 3rd quarter worth $25,000. SHP Wealth Management acquired a new stake in shares of Becton, Dickinson and Company during the fourth quarter worth $26,000. Meeder Asset Management Inc. boosted its position in shares of Becton, Dickinson and Company by 152.2% in the first quarter. Meeder Asset Management Inc. now owns 169 shares of the medical instruments supplier’s stock valued at $27,000 after acquiring an additional 102 shares during the period. Main Street Group LTD bought a new stake in shares of Becton, Dickinson and Company in the first quarter valued at about $29,000. Finally, Prosperity Bancshares Inc acquired a new position in shares of Becton, Dickinson and Company in the fourth quarter valued at about $29,000. 86.97% of the stock is currently owned by institutional investors.

Becton, Dickinson and Company Stock Up 0.7%

Shares of NYSE BDX opened at $183.16 on Friday. The stock has a market capitalization of $50.47 billion, a P/E ratio of 55.17, a PEG ratio of 12.82 and a beta of 0.19. The stock’s fifty day moving average is $157.84 and its 200 day moving average is $161.70. Becton, Dickinson and Company has a 52 week low of $127.59 and a 52 week high of $187.35. The company has a debt-to-equity ratio of 0.55, a quick ratio of 0.51 and a current ratio of 0.87.

Becton, Dickinson and Company (NYSE:BDX) last posted its quarterly earnings data on Thursday, August 6th. The medical instruments supplier reported $3.23 earnings per share for the quarter, topping the consensus estimate of $3.14 by $0.09. The business had revenue of $4.98 billion during the quarter, compared to analysts’ expectations of $4.89 billion. Becton, Dickinson and Company had a net margin of 4.52% and a return on equity of 14.79%. Becton, Dickinson and Company’s revenue was up 5.4% compared to the same quarter last year. During the same quarter in the prior year, the business posted $3.68 earnings per share. Becton, Dickinson and Company has set its FY 2026 guidance at 12.620-12.720 EPS. Sell-side analysts forecast that Becton, Dickinson and Company will post 12.67 earnings per share for the current fiscal year.

Becton, Dickinson and Company Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Wednesday, September 30th. Stockholders of record on Wednesday, September 9th will be issued a dividend of $1.05 per share. This represents a $4.20 dividend on an annualized basis and a dividend yield of 2.3%. The ex-dividend date of this dividend is Wednesday, September 9th. Becton, Dickinson and Company’s dividend payout ratio is 126.51%.

Insider Buying and Selling

In other Becton, Dickinson and Company news, EVP Michael David Garrison sold 1,100 shares of the company’s stock in a transaction on Wednesday, June 24th. The stock was sold at an average price of $145.66, for a total transaction of $160,226.00. Following the completion of the sale, the executive vice president directly owned 13,172 shares in the company, valued at $1,918,633.52. This represents a 7.71% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Roland Goette sold 2,438 shares of the firm’s stock in a transaction on Tuesday, August 11th. The shares were sold at an average price of $180.84, for a total value of $440,887.92. Following the completion of the sale, the executive vice president directly owned 14,856 shares in the company, valued at approximately $2,686,559.04. This represents a 14.10% decrease in their position. The SEC filing for this sale provides additional information. In the last 90 days, insiders have sold 11,779 shares of company stock worth $1,974,669. Corporate insiders own 0.40% of the company’s stock.

Wall Street Analyst Weigh In

A number of equities analysts recently commented on the stock. Citigroup reaffirmed a “buy” rating on shares of Becton, Dickinson and Company in a research report on Thursday. The Goldman Sachs Group decreased their target price on shares of Becton, Dickinson and Company from $156.00 to $150.00 and set a “neutral” rating on the stock in a research report on Wednesday, May 27th. UBS Group initiated coverage on shares of Becton, Dickinson and Company in a report on Tuesday, July 28th. They set a “buy” rating and a $190.00 target price on the stock. Royal Bank Of Canada lifted their price target on shares of Becton, Dickinson and Company from $180.00 to $190.00 and gave the company a “sector perform” rating in a research report on Thursday. Finally, Barclays boosted their price target on Becton, Dickinson and Company from $202.00 to $204.00 and gave the company an “overweight” rating in a research note on Monday, May 11th. Eight equities research analysts have rated the stock with a Buy rating, eight have assigned a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat, the stock has an average rating of “Hold” and a consensus price target of $185.67.

About Becton, Dickinson and Company

Becton, Dickinson and Company (BDX) is a global medical technology company that develops, manufactures and sells a broad range of medical devices, instrument systems and reagents. BD’s products are used by healthcare institutions, clinical laboratories, life science researchers and the pharmaceutical industry to enable safe, effective delivery of care, specimen collection and diagnostic testing. The company’s operations span multiple business areas focused on medical devices, life sciences research tools and interventional technologies.

BD’s product portfolio includes single-use medical devices such as syringes, needles, needlesafety and injection systems, infusion therapy and medication management solutions, as well as vascular access, urology and oncology devices acquired through its interventional business.